Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 1
2008 1
2009 3
2010 6
2011 3
2012 7
2013 9
2014 7
2015 8
2016 11
2017 9
2018 16
2019 19
2020 23
2021 25
2022 28
2023 33
2024 46
2025 62
2026 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
BACKGROUND: AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced br …
BACKGROUND: AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AK …
Overcoming Endocrine Resistance in Breast Cancer.
Hanker AB, Sudhan DR, Arteaga CL. Hanker AB, et al. Cancer Cell. 2020 Apr 13;37(4):496-513. doi: 10.1016/j.ccell.2020.03.009. Cancer Cell. 2020. PMID: 32289273 Free PMC article. Review.
Estrogen receptor-positive (ER(+)) breast cancer is the most common breast cancer subtype. Treatment of ER(+) breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as end …
Estrogen receptor-positive (ER(+)) breast cancer is the most common breast cancer subtype. Treatment of ER(+) …
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. Bidard FC, et al. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1. N Engl J Med. 2025. PMID: 40454637 Clinical Trial.
BACKGROUND: Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Camizestrant, a next-generation selective …
BACKGROUND: Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cy …
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, Graf RP, Kalinsky K. Bhave MA, et al. Breast Cancer Res Treat. 2024 Oct;207(3):599-609. doi: 10.1007/s10549-024-07376-w. Epub 2024 Jun 14. Breast Cancer Res Treat. 2024. PMID: 38872062 Free PMC article.
BACKGROUND: The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP …
BACKGROUND: The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 …
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO, Spring LM, Bardia A, Wander SA. Brett JO, et al. Breast Cancer Res. 2021 Aug 15;23(1):85. doi: 10.1186/s13058-021-01462-3. Breast Cancer Res. 2021. PMID: 34392831 Free PMC article. Review.
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. ...These therapies include estrogen receptor-targeting agents, such as se …
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the …
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.
Hao C, Wei Y, Meng W, Zhang J, Yang X. Hao C, et al. Cancer Treat Rev. 2025 Jan;132:102861. doi: 10.1016/j.ctrv.2024.102861. Epub 2024 Nov 19. Cancer Treat Rev. 2025. PMID: 39662202 Free article. Review.
In hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, aberrations in this pathway are increasingly recognized as key drivers of resistance to endocrine therapy and cyclin-dependent kinase 4 …
In hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, aberratio …
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Browne IM, André F, Chandarlapaty S, Carey LA, Turner NC. Browne IM, et al. Lancet Oncol. 2024 Apr;25(4):e139-e151. doi: 10.1016/S1470-2045(23)00676-9. Lancet Oncol. 2024. PMID: 38547898 Review.
The growing availability of targeted therapies for patients with advanced oestrogen receptor-positive breast cancer has improved survival, but there remains much to learn about the optimal management of these patients. ...Approvals for oestrogen receptor-positive ad …
The growing availability of targeted therapies for patients with advanced oestrogen receptor-positive breast cancer has improv …
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Turner N, et al. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18. Future Oncol. 2023. PMID: 37070653 Free article.
Camizestrant is a next-generation oral selective estrogen receptor degrader (SERD) that in a phase II study significantly improved progression-free survival (PFS) over fulvestrant (also a SERD) in ER+/HER2- ABC. ...Here we describe the SERENA-6 clinical trial …
Camizestrant is a next-generation oral selective estrogen receptor degrader (SERD) that in a phase II study significantly impr …
Targeted and cytotoxic inhibitors used in the treatment of breast cancer.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2024 Dec;210:107534. doi: 10.1016/j.phrs.2024.107534. Epub 2024 Dec 2. Pharmacol Res. 2024. PMID: 39631485 Free article. Review.
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. ...Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breas …
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. ...Patients wi …
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group. Oliveira M, et al. Lancet Oncol. 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. Lancet Oncol. 2024. PMID: 39214106 Clinical Trial.
BACKGROUND: CAPItello-291 is an ongoing phase 3 trial in which capivasertib-fulvestrant significantly improved progression-free survival versus placebo-fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had relaps …
BACKGROUND: CAPItello-291 is an ongoing phase 3 trial in which capivasertib-fulvestrant significantly improved progression-free survi …
324 results